辛伐他汀治疗非酒精性脂肪性肝病疗效的Meta分析  

Meta-analysis of the efficacy of Simvastatin in the treatment of nonalcoholic fatty liver disease

作　　者：张改萍[1] 田晓英[1] 宋叶君 孟小玲[1] 杜金星 周冉 张思宇 侯学琳 赵芳 韩炜[1] Zhang Gaiping;Tian Xiaoying;Song Yejun;Meng Xiaoling;Du Jinxing;Zhou Ran;Zhang Siyu;Hou Xuelin;Zhao Fang;Han Wei(Department of Nursing,Taiyuan Third People′s Hospital,Taiyuan,Shanxi 030001,China)

机构地区：[1]太原市第三人民医院护理部,山西太原030001

出　　处：《中国药物与临床》2023年第8期486-491,共6页Chinese Remedies & Clinics

基　　金：太原市“六个一批”卫生健康人才能力提升专项行动项目(Y2023004)。

摘　　要：目的 系统评价辛伐他汀药物治疗非酒精性脂肪性肝病(NAFLD)的临床疗效。方法 在中国知网、万方数据库、PubMed中检索2023年9月前公开发表的关于辛伐他汀治疗NAFLD的随机对照试验。筛选文献提取数据后,对纳入研究进行质量评价,运用Review Manage 5.4.1软件进行Meta分析。结果 纳入12篇研究,共1 090例患者。Meta分析结果显示,试验组总有效率高于对照组[OR(95%CI):3.72(2.50,5.53),P<0.01],试验组患者谷丙转氨酶(ALT)[MD(95%CI):-13.45(-17.11,-9.80),P<0.01],天冬氨酸转氨酶(AST)[MD(95%CI):-12.58(-16.09,-9.07),P<0.01],γ-谷氨酰转移酶(γ-GT)[MD(95%CI):-25.74(-34.47,-17.01),P<0.01],三酰甘油(TG)[MD(95%CI):-0.50(-0.79,-0.21),P=0.0008]水平低于对照组,上述指标差异均具有统计学意义。但试验组患者总胆固醇(TC)[MD(95%CI):-0.80(-1.66,0.06),P=0.07],低密度脂蛋白胆固醇(LDL-C)[MD(95%CI):-0.27(-0.69,0.15),P=0.21]水平略低于对照组,差异不具有统计学意义。结论 辛伐他汀联合其他药物治疗NAFLD患者的疗效优于单独使用该药物的疗效,可有效降低患者ALT、AST、γ-GT和TG水平。Objective To evaluate the clinical efficacy of simvastatin in the treatment of nonalcoholic fat-ty liver disease systematically.Methods CNKI,Wanfang,and PubMed were searched for randomized controlled trials published before September 2023 on simvastatin in the treatment of nonalcoholic fatty liver disease.After screening the literature to extract data,the quality of the included studies was assessed and Meta-analysis was performed using Review Manage 5.4.1 software.Results Twelve studies with a total of 1090 patients were in-cluded.The results of Meta-analysis showed that the total effective rate of the experimental group was higher than that of the control group[OR=3.72,95%CI:(2.50,5.53),P<0.01],the levels of ALT[MD=-13.45,95%CI:(-17.11,-9.80),P<0.01],AST[MD=-12.58,95%CI:(-16.09,-9.07),P<0.01],γ-GT[MD=-25.74,95%CI:(-34.47,-17.01),P<0.01]and TG[MD=-0.50,95%CI:(-0.79,-0.21),P=0.0008]in the experimental group were significantly lower than those of the control group,and the differences in the above indicators were statistically significant.However,the levels of TC[MD=-0.80,95%CI:(-1.66,0.06),P=0.07]and LDL-C[MD=-0.27,95%CI:(-0.69,0.15),P=0.21]in the experimental group were slightly lower than those in the control group,and the differences were not statisti-cally significant.Conclusion The efficacy of simvastatin combined with other drugs in the treatment of NAFLD patients is better than that of NAFLD alone,which can effectively reduce the levels of ALT,AST,γ-GT and TG.

关 键 词：非酒精性脂肪性肝病 辛伐他汀 META分析 脂肪肝 抗脂肝药 

分 类 号：R575.5[医药卫生—消化系统]